Sector News

Featured News

June 19, 2022
Sustainability

Borderless is proud to announce that it has recently received a Bronze award from Ecovadis. An initial assessment of the firm’s performance in environmental, labor and human rights matters, placed the firm in the top 50% of companies assessed by Ecovadis.

Latest News

March 19, 2023
Life sciences

With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.

March 19, 2023
Diversity & Inclusion

It’s been nearly 60 years since the Equal Pay Act, and while women have made major strides both in the workforce and in higher education, the gains are far from equitable. In honor of Equal Pay Day, four Chief Members share the barriers women face when it comes to earning fair pay, and the policies and practices leaders should implement now to really move the needle forward.

March 19, 2023
Sustainability

The transition to low-carbon energy has the potential to create massive economic opportunities and benefit individuals and communities across the globe. But if not managed properly, the energy transition could also bring high costs and inequities, often for the world’s most vulnerable populations.

March 19, 2023
Borderless Leadership

The Great Resignation seemed to peak in November 2021, when a record 4.5 million workers quit their jobs in a single month. Desperate to retain employees, companies were scrambling. They offered more flexible work. Now, with layoffs and return-to-office mandates, business leaders are wrenching back power. But it’s not as bad as you might think.

March 19, 2023
Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

Subscribe to our Weekly Newsletter

Understanding your business is our business

How can we help you?

We're easy to reach